Weve heard a lot about glucagon-like peptide 1 (GLP-1) receptor agonists lately, primarily via the brand names Ozempic and Wegovy
doi:10.3389/fphar.2022.935823
When used in conjunction with other GLP-1 based therapies like Cagrisema, this dual-action could potentiate greater advancements toward effective weight control as well as enhanced glycemic managementa substantial boon for individuals dealing with obesity or diabetes-related health issues
The implication for budget models was immediate and the adjustment was made in the quarter the ruling was issued
Ben Blanc 27:22 Well, thanks Robert for all these insights, so many learnings in this episode, and thats it for this special episode of Healthcare Matters, live from the world vaccine Congress
Real-world patients also tend to have more lifestyle support, ongoing medical relationships, and gradual dose reductions compared to the abrupt cessation in clinical trials